ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting

    Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate

    Manfred Herold1, Peter Fasching2, Winfried Graninger3, Raimund Lunzer4, Omid Zamani5 and Burkhard Leeb6, 1Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 2Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 3Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 4Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 5Rheumazentrum Favoriten Vienna, Wien, Austria, 62nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria

    Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
  • Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity

    Manfred Herold1, Peter Fasching2, Winfried Graninger3, Raimund Lunzer4, Omid Zamani5 and Burkhard Leeb6, 1Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 2Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 3Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 4Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 5Rheumazentrum Favoriten Vienna, Wien, Austria, 62nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria

    Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
  • Abstract Number: 569 • 2015 ACR/ARHP Annual Meeting

    Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy

    Byeongzu Ghang1, Doo-Ho Lim2, Soo Min Ahn3, Wook Jang Seo4, Seokchan Hong3, Yong-Gil Kim2, Chang-Keun Lee2 and Bin Yoo2, 1Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 4Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

    Background/Purpose: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an effective drug for the treatment of rheumatoid arthritis (RA). During administration of tocilizumab, previous studies have…
  • Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting

    Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis

    Masao Sato1 and Masao Takemura2, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan

    Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
  • Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients

    Virginia Ruiz-Esquide1, Azucena Gonzalez-Navarro2, Jordi Yagüe3, Jose Inciarte-Mundo1, M. Victoria Hernández1, Julio Ramirez1, Sonia Cabrera-Villalba1, Juan D. Cañete1 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 3Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain

    Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
  • Abstract Number: 2481 • 2014 ACR/ARHP Annual Meeting

    Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDs in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months

    Jacques Tebib1, Isabelle Idier2, Mathieu Coudert3, David Pau4, Rene-Marc Flipo5 and Jean-Francis Maillefert6, 1Rheumatology, University Hospital Lyon, Lyon, France, 2Chugai Pharma, La Defense, France, 3Statistics, Experis IT, Nanterre, France, 4Statistics, Roche, Boulogne-Billancourt, France, 5Rheumatology, University Hospital Lille, Lille, France, 6Rheumatology, University Hospital Dijon, Dijon, France

    Background/Purpose Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
  • Abstract Number: 2479 • 2014 ACR/ARHP Annual Meeting

    Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis

    Shuntaro Saito, Keisuke Izumi, Yuko Kaneko, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose Interleukin-6 (IL-6) is considered a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a monoclonal antibody which binds to membrane-bound…
  • Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT

    Koichi Okamura1, Yukio Yonemoto1, Chisa Okura2 and Kenji Takagishi1, 1Orthopaedic Surgery, Gunma University, Maebashi, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

    Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
  • Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency

    Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan

    Background/Purpose:  Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
  • Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting

    IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis

    Atsuma Nishiwaki1, Hitomi Kobayashi2, Yasuyuki Kobayashi3, Isamu Yokoe1, Noboru Kitamura2, Hidetake Shiraiwa1, Takamasa Nozaki1, Hirotake Inomata2, Natsumi Ikumi4, Kaita Sugiyama1, Yousuke Nagasawa1 and Masami Takei5, 1Nihon University School of Medicine, Tokyo, Japan, 2Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 3Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, 4Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 5Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan

    Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
  • Abstract Number: 1533 • 2014 ACR/ARHP Annual Meeting

    Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis

    Hiroshi Uda1, Koji Shigematsu2 and Osamu Saiki1, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan

    Background/Purpose:  The treatment of active rheumatoid arthritis (RA) patients are usually started with synthetic disease modifying antirheumatic drugs (DMARDs), but when adequate response are not…
  • Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting

    Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA

    Kazuyuki Yoshizaki, Osaka University, Osaka, Japan

    Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
  • Abstract Number: 1179 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging

    Michihito Kono1, Shinsuke Yasuda1, Kazumasa Ohmura1, Tomoko Fukui1, Sanae Shimamura1, Ikuma Nakagawa1, Atsushi Noguchi1, Haruki Shida1, Toshiyuki Watanabe1, Yuka Shimizu1, Takashi Kurita1, Kenji Oku1, Toshiyuki Bohgaki1, Olga Amengual1, Tetsuya Horita1, Keita Sakamoto2, Tamotsu Kamishima3 and Tatsuya Atsumi1, 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 3Hokkaido University, Faculty of Health Science, Sapporo, Japan

    Background/Purpose: Magnetic Resonance Imaging (MRI) has been established as a useful modality to evaluate synovitis, bone edema, and bone erosion in patients with rheumatoid arthritis…
  • Abstract Number: 506 • 2014 ACR/ARHP Annual Meeting

    Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis

    Osamu Saiki1, Hiroshi Uda1 and Koji Shigematsu2, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan

    Background/Purpose: For active rheumatoid arthritis (RA) patients with inadequate response to synthetic DMARDs, biologic agents, such as TNF inhibitor and IL-6 receptor inhibitor, are indicated.…
  • Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting

    Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience

    Francesca De Nard1, Vittorio Grosso2, Monica Todoerti3, Carlomaurizio Montecucco4 and Roberto Caporali5, 1Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 2Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, 3Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 4Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, 5Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy

    Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology